Open Access Editorial
Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?
Georgios Iatrakis1,
, Stefanos Zervoudis1,2,Angeliki Sarella1
, Panagiotis Tsikouras3, Minas Paschopoulos5, Myrsini Balafouta1, Panagiotis Peitsidis 4,*
1 University of West Attica, Athens, Greece
5 University of Ioannina, Greece
*Corresponding author: Dr. Panagiotis Peitsidis PhD Msc, Obstetrician Gynecologist, Helena Venizelou Hospital Athens, Greece.
Email: peitsidiobgyn@gmail.com
Download PDF
Published: 22 February 2024; https://doi.org/10.61873/OEFM7580
An Erratum to this article was published on 11 March 2024
Abstract
Tamoxifen is a nonsteroidal selective estrogen receptor modulator that is used mainly for adjuvant treatment of estrogen receptor-positive breast cancer. However, tamoxifen, due to its estrogen-mimicking effects, has been linked to various uterine conditions including menstrual irregularities, and endometrial cancer. Considering that in women taking tamoxifen, ultrasonographical endometrial thickness can be increased without an underlying pathology and that the tamoxifen induces only an extra endometrial cancer in 1 per 1000 women per year of use, patients undergoing tamoxifen treatment don’t typically undergo regular examinations of the endometrium, including ultrasonography. Routine ultrasonographic screening for endometrial lesions could result in excessive intervention for non-symptomatic endometrial conditions, undue stress, and might even negatively affect patients’ adherence to tamoxifen therapy, which is crucial for reducing breast cancer recurrence and mortality. Nevertheless, if any unusual bleeding arises, an endometrial evaluation is necessary.
Keywords: tamoxifen, endometrial thickness, ultrasound, breast cancer
Please cite as: